Triferic’s Modified Indication Gets Past FDA Panel Despite Real World Applicability Concerns
This article was originally published in The Pink Sheet Daily
Executive Summary
Oncologic Drugs Advisory Committee endorses approval of Rockwell’s Triferic, but for only half of proposed indication; support tempered by “artificial” nature of Phase III studies, a claim to which Rockwell’s CMO agreed.
You may also be interested in...
Rockwell Sees Opportunity For Triferic In Cost-Sensitive CKD Market
Rockwell Medical has filed an NDA for the iron replacement therapy, which will be positioned as an alternative to I.V. iron during dialysis and could limit the need for erythropoietin-stimulating agents.
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.
Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests
The rulemaking is supposed to formalize the Patent Trial and Appeal Board process, which has been in an interim status since a Supreme Court decision, giving manufacturers more ability to request oversight of the decisions.